In this video, Dr. Brian GM Durie explains why kappa and lambda levels typically decrease for myeloma patients.

While lambda and kappa levels may lower, it’s usually not concerning. 

Have a question? Submit it to

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at

Previous Post
Global Collaboration Essential to Achieve a Cure for Myeloma
Next Post
Why expertise is important in guiding treatment planning, myeloma research, and much more

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.